153982-08-2

Basic information

• Product Name: Butanoic acid, 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxo-
• CAS NO: 153982-08-2
• Molecular Formula: C11H13N3O3
• Molecular Weight: 235.243
• Mol File: 153982-08-2.mol

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxo-(153982-08-2)
• EPA Substance Registry System: Butanoic acid, 4-[[4-(aminoiminomethyl)phenyl]amino]-4-oxo-(153982-08-2)

Safety Data

• Hazardous Substances Data: 153982-08-2(Hazardous Substances Data)

Upstream product

• 108-30-5 succinic acid anhydride 
• 2498-50-2 4-aminobenzamidine dihydrochloride 

Downstream Products

• 149519-82-4 ethyl β-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-1,3-benzodioxole-5-propanoate 

Relevant articles and documents

IIB/IIIA ANTAGONISTS CO-ADMINISTERED WITH ASPIRIN

The present invention is directed to coadministration of the fibrinogen receptor antagonists 3S-[[4-[[4-aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid or ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-penty

Aminobenzamidinosuccinyl lactone derivatives useful as inhibitors of platelet aggregation

This invention provides a compound of the formula or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions of such compounds and a method of treatment to inhibit aggregation of platelets.

Peptide mimics useful as platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 or pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions of such phenylamidines derivatives, and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists

Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl)penta

Substituted β-amino acid derivatives useful as platelet aggregation inhibitors

Novel substituted β amino acid derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

Substituted heterocyclic derivatives useful as platelet aggregation inhibitors

Novel substituted heterocyclic derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof

Novel substituted β amino acid derivatives are provided which inhibit platelet aggregation and intermediates thereof. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.